Correction to: Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real‑world, multi‑center, matched analysis (Annals of Hematology, (2022), 101, 9, (2001-2010), 10.1007/s00277-022-04895-8)

Shai Shimony*, Jonathan Canaani, Eitan Kugler, Boaz Nachmias, Ron Ram, Israel Henig, Avraham Frisch, Chezi Ganzel, Vladimir Vainstein, Yakir Moshe, Shlomzion Aumann, Moshe Yeshurun, Yishai Ofran, Pia Raanani, Ofir wolach

*Corresponding author for this work

Research output: Contribution to journalComment/debate

Fingerprint

Dive into the research topics of 'Correction to: Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real‑world, multi‑center, matched analysis (Annals of Hematology, (2022), 101, 9, (2001-2010), 10.1007/s00277-022-04895-8)'. Together they form a unique fingerprint.

Medicine & Life Sciences